TY  - JOUR
AU  - Hering, Svenja
AU  - Gaus, Richard
AU  - Hofmaier, Jan
AU  - Mansoorian, Sina
AU  - Marschner, Sebastian
AU  - Schmidt-Hegemann, Nina-Sophie
AU  - Mendes, Vanessa da Silva
AU  - Tufman, Amanda
AU  - Reinmuth, Niels
AU  - Landry, Guillaume
AU  - Niyazi, Maximilian
AU  - Belka, Claus
AU  - Corradini, Stefanie
AU  - Eze, Chukwuka
TI  - Prospective assessment of MR-guided single-fraction stereotactic ablative radiotherapy for peripheral lung metastases: dosimetric and clinical outcomes.
JO  - Practical Radiation Oncology
VL  - nn
SN  - 1879-8500
CY  - Amersterdam [u.a.]
PB  - Elsevier
M1  - DKFZ-2025-01182
SP  - nn
PY  - 2025
N1  - epub
AB  - This study aimed to evaluate the feasibility and safety of online MR-guided single-fraction stereotactic ablative radiotherapy (SABR) and to assess acute changes in pulmonary function tests (PFTs), inflammatory markers, patient-reported quality of life (QoL), and dosimetric outcomes.Patients with lung metastases were included in this single-center prospective study. Patients underwent MR-guided single-fraction SABR. The primary endpoints encompassed local control (LC) and overall survival (OS). Secondary endpoints included acute toxicity (CTCAE v. 5.0), changes in PFTs, inflammatory markers, QoL, and dosimetric outcomes.Between 10/2020 and 10/2022, 26 patients with 30 lung metastases were prospectively enrolled. At a median follow-up of 19.9 months (range: 16.1 - 25.6 months), the 1- and 2-year LC rates were 96.2
KW  - Single-fraction MR-guided stereotactic ablative radiotherapy (Other)
KW  - health-related quality of life (Other)
KW  - immunotherapy (Other)
KW  - lung cancer (Other)
KW  - pulmonary function parameters (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40480627
DO  - DOI:10.1016/j.prro.2025.05.006
UR  - https://inrepo02.dkfz.de/record/301912
ER  -